Pharmabiz10m
China NMPA grants marketing authorization to IMPACT Therapeutics’ Senaparib for 1L maintenance therapy in ovarian cancer
China NMPA grants marketing authorization to IMPACT Therapeutics’ Senaparib for 1L maintenance therapy in ovarian cancer: Shanghai Saturday, January 18, 2025, 15:30 Hrs [IST] IM ...
Pharmabiz40m
Caris Life Sciences collaborates with Ontada to advance oncology research and the adoption of precision medicine
Caris Life Sciences collaborates with Ontada to advance oncology research and the adoption of precision medicine: Irving, Texas Saturday, January 18, 2025, 15:00 Hrs [IST] Caris L ...
Pharmabiz1h
UAE health ministry approves Biomerica’s Fortel PSA Screening Test to detect an early sign of prostate cancer
UAE health ministry approves Biomerica’s Fortel PSA Screening Test to detect an early sign of prostate cancer: Irvine, California Saturday, January 18, 2025, 14:00 Hrs [IST] Bio ...
Pharmabiz2h
In 2024 EMA recommends 114 medicines for marketing authorisation; 46 had a new active substance
EMA recommends 114 medicines for marketing authorisation; 46 had a new active substance: Amsterdam, The Netherlands Saturday, January 18, 2025, 13:00 Hrs [IST] European Me ...
Pharmabiz2h
Avicanna enters scientific and medical affairs collaboration with Vectura Fertin Pharma
Avicanna enters scientific and medical affairs collaboration with Vectura Fertin Pharma: Toronto Saturday, January 18, 2025, 13:30 Hrs [IST] Avicanna Inc., a commercial stage, int ...
Pharmabiz3h
WHO launches US$ 1.5 billion Health Emergency Appeal to tackle unprecedented global health crises
WHO launches US$ 1.5 billion Health Emergency Appeal to tackle unprecedented global health crises: Geneva Saturday, January 18, 2025, 12:00 Hrs [IST] Conflict, climate change, epi ...
Pharmabiz4h
Boehringer Ingelheim’s phase III CONNEX clinical programme of iclepertin in schizophrenia fails to meet primary and key secondary endpoints
Ingelheim, Germany Saturday, January 18, 2025, 11:00 Hrs [IST] ...
Pharmabiz4d
DFE Pharma expands its C2F Center of Excellence in Hyderabad to advance the development of critical respiratory treatments
DFE Pharma, a global leader in pharmaceutical and biopharmaceutical excipient solutions, has expanded the capabilities of its Closer to the Formulator (C2F) Center of Excellence located in Genome ...
Pharmabiz3d
Illumina launches pilot proteomics programme with UK Biobank and biopharma collaborators to analyze 50,000 samples
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced a pilot proteomics programme to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, ...
Pharmabiz4d
India initiates anti-dumping probe on Resorcinol imports from China and Japan
The Directorate General of Trade Remedies (DGTR) has issued an updated notification concerning the ongoing anti-dumping investigation into imports of Resorcinol from China PR and Japan. The ...
Pharmabiz4d
PDMA asks govt to create separate category for units below Rs. 10 crore & allow 3 years to implement revised Schedule M
The Punjab Drug Manufacturers Association (PDMA) has sought the Union ministry of health and family welfare to create a separate category for units below Rs. 10 crore turnover outside the erstwhile ...
Pharmabiz4d
China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma
The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...